![]() |
市場調查報告書
商品編碼
1420190
北美類器官市場預測至 2030 年 - 區域分析 - 按器官類型、應用、來源和類型North America Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type, Application, Source, and Type |
北美類器官市場預計將從2022年的11.2501億美元成長到2030年的53.5972億美元。預計2022年至2030年CAGR為21.5%。
個人化藥物的日益普及推動了北美類器官市場
個人化醫療,也稱為精準醫療,是一種根據預期的反應或疾病風險為個別患者量身定製程序或藥物的醫療模式。根據個人化醫療聯盟(PMC) 發表的一項研究,2005 年個人化藥物僅佔FDA 批准的新分子實體的5%,而2016 年則佔了25% 以上。此外,佔所有化合物和藥物的42 % 73% 的研發中腫瘤化合物有潛力成為個人化藥物。此外,生物製藥公司在過去五年中對個人化藥物的研發投入幾乎加倍,未來五年可能會增加33%。生物製藥研究人員也預測,未來五年個人化藥物的開發將成長 69%。根據PMC的最新報告(2021年發布),在美國,市場上的個人化醫療數量已從2016年的132種上升到2020年的286種。該資料是透過追蹤2008年以來的個人化醫療數量來共享的。由PMC。
使用類器官來創建個人化藥物療法為改善患者護理提供了令人興奮的機會。此外,藥劑師在增加個人化藥物需求方面發揮著重要作用,因為他們積極宣傳精準醫療並提高人們的意識。最近的研究表明,超過 50% 的消費者有興趣購買客製化產品或服務。這種需求促使藥物研究發展出更有針對性的治療方法,使藥物更安全、更有效。
個人化癌症醫學是一種根據腫瘤基因組特徵為每位患者制定有效治療策略的方法。對個人化腫瘤模型研究的需求不斷增加,以確認臨床前環境中基因組藥物反應預測的功能。許多研究強調了腫瘤類器官在個人化癌症醫學中在基因藥物關聯治療、新療法鑑定和患者預後預測方面的應用。
個人化癌症治療對每位患者進行特定的治療。使用與原始腫瘤具有相似特徵的個人化腫瘤模型可能會準確預測患者的藥物反應。腫瘤類器官模型有幾個優點,例如與預先存在的模型相比,保留了原始腫瘤的分子和細胞組成。這些優點凸顯了腫瘤類器官在個人化癌症治療中的巨大潛力,特別是在臨床前藥物篩選和預測患者對選定治療方案的反應。
北美類器官市場概況
北美類器官市場分為美國、加拿大和墨西哥。 2022年,美國佔據北美類器官市場最大佔有率。患有慢性病和病毒性疾病的患者數量不斷增加、研發活動不斷增加、類器官模型的商業化以及幹細胞研究的突破是推動類器官市場的關鍵因素。此外,用於類器官開發的資金和贈款不斷增加也有利於市場擴張。
北美類器官市場收入及 2030 年預測(百萬美元)
北美類器官市場細分
北美類器官市場分為器官類型、應用、來源、類型和國家。
依器官類型,北美類器官市場分為腸、肝、胃、胰臟、肺、腦、腎等。 2022 年,腸道領域在北美類器官市場中佔據最大佔有率。
根據應用,北美類器官市場分為發育生物學疾病、傳染病病理學、再生醫學、藥物毒性和功效測試、藥物發現和個人化醫療等。 2022 年,發育生物學疾病領域佔據北美類器官市場的最大佔有率。
根據來源,北美類器官市場分為多能幹細胞和器官特異性成體幹細胞。 2022 年,多能幹細胞細分市場在北美類器官市場中佔據更大佔有率。
根據類型,北美類器官市場分為儀器、消耗品和服務。 2022 年,消耗品領域在北美類器官市場中佔據最大佔有率。
根據國家/地區,北美類器官市場分為美國、加拿大和墨西哥。 2022 年,美國在北美類器官市場佔據主導地位。
STEMCELL Technologies Inc、Cellesce Ltd、Organoid Therapeutics、3Dnamics Inc、Thermo Fisher Scientific Inc、Merck KGaA 和 InSphero 是北美類器官市場的一些領導公司。
The North America organoid market is expected to grow from US$ 1,125.01 million in 2022 to US$ 5,359.72 million by 2030. It is estimated to grow at a CAGR of 21.5% from 2022 to 2030.
Growing Adoption of Personalized Drugs Fuel North America Organoids Market
Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years. According to the latest report by the PMC (published in 2021), in the US, the number of personalized medicines in the market has risen from 132 in 2016 to 286 in 2020. The data was shared by tracking the numbers of personalized medicine since 2008 by the PMC.
The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.
Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor's genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene-drug association treatment, identification of new therapies, and prediction of patient outcomes.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.
North America Organoids Market Overview
The North America organoids market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America organoids market. Rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development, commercialization of organoid models, and breakthroughs in stem cell research are the key factors propelling the market for organoids. Also, the growing funding and grants for organoid development are favoring market expansion.
North America Organoid Market Revenue and Forecast to 2030 (US$ Million)
North America Organoids Market Segmentation
The North America organoid market is segmented into organ type, application, source, type, and country.
Based on organ type, the North America organoid market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the North America organoid market in 2022.
Based on application, the North America organoid market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest share of the North America organoid market in 2022.
Based on source, the North America organoid market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the North America organoid market in 2022.
Based on type, the North America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on country, the North America organoid market is segmented int o the US, Canada, and Mexico. The US dominated the North America organoid market in 2022.
STEMCELL Technologies Inc, Cellesce Ltd, Organoid Therapeutics, 3Dnamics Inc, Thermo Fisher Scientific Inc, Merck KGaA, and InSphero are some of the leading companies operating in the North America organoids market.